IFN-γ Upregulates Survivin and Ifi202 Expression to Induce Survival and Proliferation of Tumor-Specific T Cells by Zimmerman, Mary et al.
IFN-c Upregulates Survivin and Ifi202 Expression to
Induce Survival and Proliferation of Tumor-Specific T
Cells
Mary Zimmerman
1, Dafeng Yang
1, Xiaolin Hu
1, Feiyan Liu
1, Nagendra Singh
1, Darren Browning
1,
Vadivel Ganapathy
1, Phillip Chandler
2, Divaker Choubey
3, Scott I. Abrams
4, Kebin Liu
1*
1Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, United Stateso fA m e r i c a ,
2Immunotherapy Center, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, United States of America, 3Department of Environmental Health,
University of Cincinnati, Cincinnati, Ohio, United States of America, 4Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, United States of America
Abstract
Background: A common procedure in human cytotoxic T lymphocyte (CTL) adoptive transfer immunotherapy is to expand
tumor-specific CTLs ex vivo using CD3 mAb prior to transfer. One of the major obstacles of CTL adoptive immunotherapy is
a lack of CTL persistence in the tumor-bearing host after transfer. The aim of this study is to elucidate the molecular
mechanisms underlying the effects of stimulation conditions on proliferation and survival of tumor-specific CTLs.
Methodology/Principal Findings: Tumor-specific CTLs were stimulated with either CD3 mAb or cognate Ag and analyzed
for their proliferation and survival ex vivo and persistence in tumor-bearing mice. Although both Ag and CD3 mAb
effectively induced the cytotoxic effecter molecules of the CTLs, we observed that Ag stimulation is essential for sustained
CTL proliferation and survival. Further analysis revealed that Ag stimulation leads to greater proliferation rates and less
apoptosis than CD3 mAb stimulation. Re-stimulation of the CD3 mAb-stimulated CTLs with Ag resulted in restored CTL
proliferative potential, suggesting that CD3 mAb-induced loss of proliferative potential is reversible. Using DNA microarray
technology, we identified that survivin and ifi202, two genes with known functions in T cell apoptosis and proliferation, are
differentially induced between Ag- and CD3 mAb-stimulated CTLs. Analysis of the IFN-c signaling pathway activation
revealed that Ag stimulation resulted in rapid phosphorylation of STAT1 (pSTAT1), whereas CD3 mAb stimulation failed to
activate STAT1. Chromatin immunoprecipitation revealed that pSTAT1 is associated with the promoters of both survivin and
ifi202 in T cells and electrophoresis mobility shift assay indicated that pSTAT1 directly binds to the gamma activation
sequence element in the survivin and ifi202 promoters. Finally, silencing ifi202 expression significantly decreased T cell
proliferation.
Conclusions/Significance: Our findings delineate a new role of the IFN-c signaling pathway in regulating T cell proliferation
and apoptosis through upregulating survivin and ifi202 expression.
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Introduction
Data from extensive studies of human cancer patients and
animal models in the last two decades strongly support the
existence of an intrinsic cancer immunosurveillance system that in
the absence of external manipulation functions to protect the host
against tumor development [1,2]. In human cancer patients, a
high level of tumor-infiltrating lymphocytes and immunological
effecter molecules in the tumor microenvironment is often
correlated with prolonged survival, decreased disease recurrence
and delayed metastasis [3,4,5]. Consistent with these observations,
cytotoxic T lymphocyte (CTL) immunotherapy has been shown
to effectively suppress tumor development in certain cancer
patients [6,7,8,9,10,11,12]. Adoptive CTL transfer immunotherapy
provides the opportunity to overcome intrinsic immune suppression
and tolerance mechanisms by enabling the ex vivo selection and
expansion of highly tumor-reactive CTLs and has emerged as one
of the potentially effective treatments for patients with metastatic
cancer. However, a major obstacle to the development of effective
CTL adoptive transfer immunotherapy for patients with cancer and
other diseases has been the lack of persistence of the transferred
CTLs inthe host [13,14,15,16].Although telomere lengtheningand
telomerase activity have been linked to CTL function and
persistence [17,18,19], the molecular mechanisms underlying the
lack of persistence of the tumor-reactive CTLs in the tumor
microenvironment is largely unknown. Studies in human cancer
patients with a nonmyeloblative but lymphodepleting chemother-
apy regimen before CTL adoptive transfer failed to improve CTL
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intrinsic to the CTLs, perhaps the conditioning of CTLs prior to
adoptive transfer, might be responsible for the lack of CTL
persistence in vivo.
One of the procedures of CTL adoptive transfer immunother-
apy is ex vivo expansion of the tumor-specific CTLs with CD3 mAb
prior to adoptive transfer [6,13]. Because adequate stimulation
mediates T cell function and survival [20] and polyclonal
stimulation through the TCR/CD3 complex has the potential to
induce T cell anergy and apoptosis [21,22], we hypothesized that
expanding the tumor-specific CTLs with CD3 mAb prior to
adoptive transfer, although effective for T cell expansion, might
not optimally condition the CTLs to survive in vivo after transfer.
To test this hypothesis, we used experimental metastasis and CTL
adoptive transfer mouse models to elucidate the molecular
mechanisms underlying tumor-specific CTL persistence in the
tumor microenvironment. Our results suggest that the IFN-c-
signaling pathway may play a critical role in mediating CTL
persistence in an autocrine manner by directly regulating survivin
and ifi202 expression during T cell activation.
Methods
Mice
Female BALB/c (H-2
d) mice were used in all studies and were
purchased from the National Cancer Institute (Frederick, MD).
Mice were housed in the Medical College of Georgia animal
facility. Experiments and care/welfare were in agreement with
federal regulations and an approved protocol (Protocol # 05-12-
728*B) by the MCG/IACUC committee.
Cell lines
The cell line CMS4, kindly provided by Dr. A. Deleo
(University of Pittsburgh, Pittsburg, PA), is a primary soft tissue
sarcoma of BALB/c (H-2
d) origin. CMS4-met is a highly
metastatic subline derived from CMS4 tumor cell line as described
[23]. 5KC is a T cell hybridoma [24] kindly provided by Dr. P.
Kraj (Medical College of Georgia, Augusta, GA). P815 was
obtained from ATCC and used as a negative control cell line for
CTL specificity.
Tumor-specific CD8
+ CTLs
CD8
+ CTLs reactive against the CMS4 tumor cells were
established from wild-type (wt) BALB/c mice as previously
described [25]. Briefly, mice were immunized with viable CMS4
tumor cells (5610
5 cells given s.c. on one flank) coadministered
with anti-CTLA-4 mAb [affinity-purified hamster anti-mouse
clone UC10-4F-11, hybridoma line provided by J. Bluestone
(University of California, San Francisco, CA)] at 100 mg/
inoculation/mouse given i.p. on days 0, 3, and 6 post-tumor
transplant. Mice that were exposed to this regimen and failed to
develop primary tumors were re-challenged on the contralateral
flank with tumor cells in the absence of CTLA-4 mAb. Splenic
CD8
+ cell lines were derived from re-challenged mice, which
showed little to no additional tumor growth. CTL cultures
(2610
5 cells per well) were propagated in vitro in 24-well plates by
stimulation with irradiated (200 Gy) CMS4-met tumor cells
(1610
5 cells per well) as a source of cognate Ag, irradiated (20
Gy) syngeneic BALB/c splenocytes (5610
6 cells per well) as
feeder cells and IL-2 (60 IU/ml. Tecin, Hoffman-LaRoche,
Nutley, NJ). CTLs were purified from dead tumor cells and
spleen cells at the end of the stimulation cycle over a Ficoll
gradient and re-stimulated weekly with freshly prepared irradi-
ated tumor cells and irradiated spleen cells. For CD3 mAb
stimulation, 24-well plates were coated with anti-CD3 and anti-
CD28 mAbs (BD biosciences) at 1 mg/well in 250 mlP B S
overnight at 4uC. CTLs were then seeded in the mAb-coated
plates as in the tumor-stimulated CTLs. IL-2 (60 IU/ml) was also
added to the culture.
In vitro cytotoxicity assays
CTL cytotoxicity was assessed by
51Cr-release assays as
previously described [26]. Briefly, target cells were labeled with
Na2
51CrO4 (ICN Biomedical). CTLs were recovered from culture
by centrifugation over a Ficoll-Hypaque gradient. CTLs and
radiolabeled target cells were then coincubated in 96-well, U-
bottom plates at various effector/target ratios. After incubation for
18 hr, supernatants were collected using a Supernatant Collection
System (Skatron Co., Sterling, VA). Radioactivity was quantitated
using a c-counter. Percent specific
51Cr-release was calculated
according to the following formula: % specific lysis = [(experi-
mental cpm-spontaneous cpm)/(total cpm-spontaneous cpm)] x
100%. Total
51Cr-release was obtained by adding 0.2% Triton X-
100 (final concentration) to the wells. Data are reported as the
mean 6 SD of triplicate wells, and representative of one of two
separate experiments.
Experimental lung metastasis model
Female BALB/c (H-2
d) mice were obtained from the National
Cancer Institute (Frederick, MD). CTL adoptive transfer immu-
notherapy was carried out essentially as previously described [27].
Briefly, CMS4-met tumor cells (2.5610
5 cells/mouse) were
injected into mice i.v. in 100 ml HBSS. CTLs were stimulated
for 4 days and purified from the culture mixture as described
above and injected to the tumor-bearing mice three days later.
Mice were sacrificed at the time points indicated. Lungs were
inflated with a 15% solution of India ink, resected, and fixed in
Fekete’s solution (60% ethanol, 10% formaldehyde, and 5%
glacial acetic acid). The number of lung nodules was enumerated
in all four lobes in a single-blinded fashion. Values exceeding 250
nodules were considered too numerous to count accurately and,
therefore, were reported as $250.
Histological Analysis
Lungs were excised from tumor-bearing mice and fixed in 10%
formalin. Sections were cut from formalin-fixed, paraffin-embed-
ded, tumor-bearing lungs, and stained with hematoxylin and
eosin.
Persistence of adoptively-transferred CTLs in vivo
CMS4-met tumor cells (2610
5/mouse) were injected i.v. into
naive mice. Five days later, CTLs were labeled with CFSE using
the CellTrace
TM
CFSE Proliferation Kit (Invitrogen) according to
the manufacturer’s instructions. CFSE-labeled CTLs (1610
6/
mouse) were injected i.v. into tumor-bearing mice. Four days later,
lungs were removed and digested with an enzyme mixture
containing hyaluronidase (0.1 mg/ml), collagenase (1 mg/ml),
and DNase I (30 U/ml), all obtained from Sigma-Aldrich, to
generate single cell suspensions. The cell suspensions were then
analyzed by flow cytometry to detect CFSE-positive cells.
Proliferation and apoptosis assay
CTLs were labeled with CFSE as described above. CFSE-
labeled CTLs were then stimulated with either the H-2L
d-resticted
peptide AH1 (SPSYVYHQF) [23] as antigen and irradiated spleen
cells as feeder cells or with the CD3 mAb plus CD28 mAb and
recombinant IL-2 as described above. Cells were stained with
IFN-c and T Cell Persistence
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three days after stimulation and analyzed by flow cytometry. Cell
proliferation was then analyzed with Modfit program (Verity
Software House, Topsham, ME) to compare the division times of
the cells under both stimulation conditions.
3H thymidine incorporation assay
CTLs were mixed with irradiated CMS4-met cells and
splenocytes as described above and seeded in flat-bottom 96-well
plates at a density of 5610
4 CTLs/well in 100 ml medium.
Mixtures of irradiated tumor cells and splenocytes without CTLs
were used as the background control. For CD3 stimulation, CTLs
at the same density were seeded in CD3 and CD28 mAb-coated
96-well plates. Approximately 24 hrs later,
3H-thymidine (10 mCi/
well) was added to the cell cultures and incubated for another
24 hrs. Cells were harvested and counted for
3H thymidine
incorporation
3H thymidine incorporation (CPM counts) was
calculated by the formula: CPM counts of the culture mixture of
irradiated tumor cells, feeder cells and CTLs mixture – CPM
counts of the culture mixture of irradiated tumor cell and feeder
cells. Cell growth rate was also measured by MTT assay (ATCC,
Manassas, VA). Cells were seeded in 96-well plates in 100 ml
culture medium for approximately 48 h. MTT (10 ml) were then
added and cultured for another 2–3 h. Cells were lysed with
detergent and measured at OD570 according to the manufactur-
er’s instruction.
Gene Silencing
Scramble shRNA (Cat# sc-108080) and ifi202-specific shRNA-
expressing lentiviral particles were obtained from Santa Cruz
Biotech (Cat# sc-40698-V). 5KC cells were transduced with the
viral particles and selected for stable lines with puromycin
according to the manufacturer’s instructions.
RT-PCR Analysis
Total RNA isolation and cDNA synthesis was carried out as
previously described [28]. For isolation of total RNA from
stimulated CTLs, tumor-stimulated CTLs were purified with
CD8 mAb-conjugated magnet beads (Invitrogen) and lysed for
total RNA. CD3 mAb-stimulated cells were harvested from the
plates and lysed for total RNA. The cDNA was then used as
templates for PCR amplification of various genes using gene-
specific primers. The following parameters were used: 30 sec at
94uC, 30 sec at 60uC, and 1 min at 72uC. PCR amplification for
all genes was first performed using 30 cycles. The PCR reactions
were then repeated using less or more cycles for optimal
amplification. PCR primers are listed in table 1.
Western Blot Analysis
Cells were lysed in lysis buffer (20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100) plus proteinase
and phosphotase inhibitor cocktails (Calbiochem, San Diego, CA)
for 60 min on ice. Proteins were separated on a 4–20% SDS-
polyacrylamide gradient gel, and transferred to PVDF membrane
(Millipore, Bedford, MA). Anti-survivin (Santa Cruz Biotech), anti-
pSAT1 (BD biosciences), anti-STAT1 (BD biosciences), and anti-
b-actin mAb (Sigma) were used as the primary Abs, followed by
incubation with horseradish peroxidase-conjugated anti-goat
(Santa Cruz Biotech, Santa Cruz, CA), anti-mouse or rabbit
(Amersham-Pharmacia, Sunnyvale, CA) IgGs. Antiserum to p202
protein, which detects both the p202a and p202b proteins has
been described [29]. Immunodetection was performed using the
ECL Plus kit (Amersham-Pharmacia).
Cell surface marker analysis
Cells were incubated with biotin-conjugated anti-mouse IFN-
cR mAb (BD biosciences), followed by incubation with PE/Cy5-
conjugated Streptavidin (BD Biosciences, CA). Control prepara-
tions were incubated with the appropriate fluorescently labeled
isotype-matched IgG. The stained cells were washed and analyzed
by flow cytometry.
Genome-wide gene expression analysis
Total RNA was isolated from cells using Trizol (invitrogen) and
used for cDNA probe preparation. cDNA probes were synthesized
using the FairPlay microarray labeling kit (Stratagene, La Jolla,
CA). The cDNA probes were then labeled with Cy3 or Cy5
monofunctional reactive dye (Amersham Biosciences, Piscataway,
NJ). The appropriate Cy3 and Cy5 labeled probes were combined
and used to probe the processed mouse oligo microarray chips
(approximately 36,000 sequences of transcripts). Fluorescent
images were captured using a Genepix 4000 (Axon Instruments,
Union City, CA). Both image and signal intensity data were
loaded into a database supported by the Center for Information
Technology (CIT) of NIH. Cy3:Cy5 intensity ratios from each
gene were calculated and subsequently normalized to ratios of
overall signal intensity from the corresponding channel in each
Table 1. PCR primer and EMSA probe sequences.
Name Sequence
PCR
Cycle #
Perforin F: 59-CCACAGGCTCATCTCCTCCTATG-39
R: 59-TCCACCAGACCAGGGTTGC-39
30
Granzyme A F: 59- CCTGAAGGAGGCTGTGAAAGAATC -39
R: 59- CCTGCTACTCGGCATCTGGTTC -39
30
Granzyme B F: 59-GCCCACAACATCAAAGAACAGG-39
R: 59-CCAGAATCCCCCCGAAAGG-39
30
FasL F: 59-CTTGGGCTCCTCCAGGGTCAGT-39
R: 59-TCTCCTCCATTAGCACCAGATCC-39
30
IFN-c F: 59- ATGGCTGTTTCTGGCTGTTACTG -39
R: 59- GCTTCCTGAGGCTGGATTCC -39
30
TNFa F: 59- TGACAAGCCTGTAGCCCACG -39
R: 59- GACTCCAAAGTAGACCTGCCCG –39
30
LTa F: 59-TGCCAGGACAGCCCATCCAC-39
R: 59-TGAGCAGGAACACAGCCCC-39
30
LTb F: 59-TGGATGACAGCAAACCGTCG-39
R: 59-AACGCTTCTTCTTGGCTCGC-39
30
LIGHT F: 59-GGCTGGAACAGAACCACCG-39
R: 59 -CCAAGTCGTGTCTCCCATAACAGAG-39
30
ifi202 F: 59- CTCCAACTCTTCTCCTTTCACCTG -39
R: 59- TGGCTCTTCACCTCAGACACG -39
28
ifi202 (ChIP) F: 59- ATGAGAAGGAGGTGGGGATGAGTG -39
R: 59- CCAGAAAAATAGTCACAAGGACGC -39
35
HPRT F: 59- CTTGCTGGTGAAAAGGACCTCTC -39
R: 59- CAAATCAAAAGTCTGGGGACGC -39
30
b-actin F: 59-ATTGTTACCAACTGGGACGACATG-39
R: 59-CTTCATGAGGTAGTCTGTCAGGTC-39
30
survivin F: 59-GCAAAGGAGACCAACAACAAGC-39
R: 59-CCACAAAACCAAAGAGAGGTAGCC-39
30
survivin (ChIP) F: 59- AGCAAGCAGTGGGAGCACGG -3
R: 59- CCAACTTCAGGAGAGCGTTTATTG -3
38
Survivin (EMSA) F: 59-TAAAGACTTCCCAGAATTCCAA-39
R: 59-TTGGAATTCTGGGAAGTCTTTA-39
38
F: forward. R: reverse.
doi:10.1371/journal.pone.0014076.t001
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database as text files, and analyzed using computer software JMP
(SAS Institute, Cary, NC). All microarray data are MIAME
compliant and are deposited in GEO database (accession #
GSE22890).
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were carried out essentially according to protocols
from Upstate (Lake Placid, NY) as previously described [30].
Briefly, cells (approximately 3610
6 per assay) were fixed in 10%
formaldehyde for 10 min at 37uC, lysed in SDS lysis buffer on ice
for 10 min, and sonicated with a 60 Sonic Dismembrator (Fisher
Scientific, Pittsburgh, PA). The lysate was pre-cleared with a
mixture of 0.04% sheared salmon sperm DNA, 0.1% BSA, and
agarose-protein A beads (Upstate) for 60 min at 4uC. The pre-
cleared supernatants were then incubated with anti-pSTAT1
antibody (Santa Cruz Biotech) or mouse IgG mAb (5 mg antibody
per assay) overnight at 4uC. A mixture (approximately 25 ml per
assay) of shared DNA, BSA, and agarose-protein A beads was then
added to the lysate and incubated at 4uC for 60 min. The beads
were then extensively washed. The protein-DNA complexes were
eluted from beads and the crosslinking was reversed. The DNA
was purified from the eluted solution and used for PCR.
Protein-DNA Interaction Assay
Electrophoresis mobility shift assays (EMSA) were carried out as
previously described [30]. The end-labeled probes were incubated
with nuclear extracts (20 mg) in the binding buffer [10 mM Tris-
HCl, pH 7.5, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT,
50 mM NaCl, 4% Glycerol, and 0.05 mg/ml poly(dI-dC).poly(dI-
dC)] for 20 min at room temperature. For specificity controls,
unlabeled probe was added to the reaction at a 1:100 molar excess.
Anti-pSTAT1 mAb (Santa Cruz Biotech) was also included to
identify pSTAT1-specific DNA binding. Anti-pSTAT1 was
incubated with the nuclear extracts for 30 min on ice before
addition of labeled probes. DNA-protein complexes were
separated by electrophoresis in 6% polyacrylamide gels in
45 mM Tris borate, 1 mM EDTA, pH 8.3. The gels were dried
and exposed to a phosphoimage screen (Molecular Dynamics) and
the images were acquired using a Strom 860 imager (Molecular
Dynamics). The EMSA probe sequences are listed in Table 1.
Statistical analysis
Where indicated, data were represented as the mean 6 SD.
Statistical analysis was carried out using two-sided t test, with p-
values,0.05 considered statistically significant.
Results
Cognate Ag and CD3 mAb stimulation leads to different
tumor rejection efficacy
Conventional CTL adoptive transfer cancer immunotherapy
requires ex vivo expansion of tumor-specific CTLs with CD3 mAb
before the CTLs are transferred to the patients [14,31,32].
However, the adoptively transferred CTLs often failed to persist in
the patients [14,33]. Although CD8
+ T cells can be re-stimulated
to rapidly expand using CD3 mAb, Ag-specific T cells often
gradually stop responding to re-stimulation and enter a ‘‘senes-
cence-like’’ state [34]. Therefore, we hypothesized that the lack of
persistence of adoptively transferred CTLs in the host might be
due, at least in part, to the stimulation conditions of the CTLs
before adoptive transfer. To test this hypothesis, we used a well-
established CTL adoptive transfer and experimental lung
metastasis mouse model [23,25,35] to examine the effects of
stimulation conditions on CTL persistence. These CTLs were
specific for CMS4-met sarcoma tumor cells in a dose-dependent
manner in vitro and exhibited potent tumor rejection efficacy
against transplanted CMS4-met tumors in vivo (Fig. 1A). Further-
more, mice receiving CTL adoptive transfer immunotherapy also
exhibited potent immunity against tumor re-challenge (Fig. 1B),
suggesting the development of immunological memory in the
tumor-challenged mice. Next, tumor-specific CTLs were stimu-
lated with CD3 mAb in the presence of a co-stimulation signal
(CD28 mAb) or with the cognate Ag (tumor cells) and analyzed for
tumor rejection efficacy in vivo. As shown in Fig. 1C, the tumor-
stimulated CTLs effectively rejected the transplanted tumor,
whereas the CD3 mAb-stimulated CTLs exhibited poor anti-
tumor efficacy even at a higher dose (Fig. 1C). Histological analysis
of the tumor-bearing mouse lungs revealed that metastatic foci in
the lungs are effectively destroyed by tumor-stimulated CTLs
(Fig. 1D, a1&2), but not by CD3 mAb-expanded CTLs (Fig. 1D,
b1&2). Taken together, our data suggest that ex vivo activation
conditions at least partially determine tumor rejection efficacy
in vivo.
Both cognate Ag and CD3 mAb can effectively activate
CTLs
Suboptimal stimulation of T cells can lead to anergy or
senescence in vivo [22,36,37]. To determine whether the poor
efficacy of CD3 mAb-expanded CTLs to reject the established
tumor is due to induction of T cell anergy or senescence, CTLs
were stained for cell surface expression levels of CD69 and CD25,
two markers of T cell activation, at various time points after
stimulation. Tumor cell-stimulated CD8
+ CTLs exhibited a
greater degree of CD25 activation but a lesser degree of CD69
activation compared to CD3-stimulated CTLs (Fig. 2A). However,
the overall CD69 and CD25 activation kinetics are qualitatively
similar between the Ag- or CD3 mAb-stimulated CTLs. Thus
either tumor cells or CD3 mAb effectively activated the CTLs.
To determine whether the poor tumor rejection efficacy of the
CD3 mAb-stimulated CTLs is due to lack of activation of
cytotoxic effecter mechanisms, we compared activation of the
cytotoxic pathways in the tumor-specific CTLs. The expression
kinetics of key effecter molecules (perforin, granzyme A and
granzyme B) of the perforin pathway, the Fas/FasL (FasL)
cytotoxic effecter pathways, the IFN-c (IFN-c), TNFa and
lymphotoxin (LTa,L T b and LIGHT) signaling pathways are all
very similar in CTLs under the two stimulation conditions
(Fig. 2B). Taken together, our data suggest that the decreased
tumor rejection efficacy of CD3 mAb-stimulated CTLs is not due
to defects in activation of the anti-tumor cytotoxic effecter
mechanisms.
Cognate Ag stimulation is required to maintain the CTL
proliferative potential
Our above observations suggest that the poor efficacy of the
CD3 mAb-activated CTLs to reject tumor is not due to the
activation status of the CTLs. This raises the possibility that this
inability might be due to lack of persistence of the CTLs after
transfer. To test this possibility, we labeled tumor- and CD3 mAb-
activated CTLs with CFSE tracking dye prior to transfer into
tumor-bearing mice. Four days after CTL transfer, we excised
tumor-bearing lungs and made single cell suspensions. The
survival of adoptively transferred CTLs was examined by analysis
of the CFSE-positive CTLs in the lung tumor. The rationale is that
if CTLs survive in the tumor microenvironment, they can be
detected as CFSE-positive cells. Analysis of cell suspensions from
IFN-c and T Cell Persistence
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e14076Figure 1. Antigen-activated CTLs exhibit greater tumor rejection efficacy than CD3 mAb-stimulated CTLs. A. Lytic sensitivity of CMS4-
met tumor cells to tumor-specific CTLs. Left panel: in vitro CTL cytotoxicity assay. Lytic sensitivity was assessed by
51Cr release. Tumor cell line P815
was used as a negative target control for CTL specificity. Right panel: photomicrographs of representative individual lungs of mice without (No CTL)
and with (+CTL) CTL adoptive immunotherapy. B. Anti-tumor immunological memory. Mice that received tumor cell transplantation and CTL
adoptive transfer immunotherapy (tumor-challenged) as shown in A and naive mice were challenged approximately 90 days after CTL
immunotherapy with the CMS4-met tumor cells and analyzed for lung metastasis. The number of tumor nodules were quantified and shown at the
right. Each dot represents total tumor nodule counts from a single mouse. C. Tumor-activated CTLs exhibited much greater tumor rejection efficacy
than CD3 mAb-stimulated CTLs. CMS4-met tumor cells were injected i.v. into mice. Three days later, saline (Control, no CTL) or tumor-specific CTLs
were injected into the tumor-bearing mice i.v. at the doses indicated. CTLs were either stimulated with irradiated tumor cells or with CD3 mAbs and
were adoptively transferred to the tumor-bearing mice. Shown are photomicrographs of individual lungs of mice (top panel). Bottom panel:
quantification of total pulmonary nodules of individual mice as shown in top panel. Each dot represents the total tumor nodule counts from a single
mouse. D. Histological analysis of lung metastasis. CMS4-met cells were injected into naı ¨ve mice iv, three days later, tumor cell-stimulated (a1 and a2)
and CD3 mAb-stimulated (b1 and b2) CTLs were injected into the tumor-bearing mice, respectively. Lungs were excised one (a1 and b1) and three (a2
and b2) days after CTL adoptive transfer and subject to histological analysis with H&E staining.
doi:10.1371/journal.pone.0014076.g001
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activated CTLs are present in the tumor-bearing lungs
(Fig. 3A&B), in contrast, much less CD3 mAb-stimulated CTLs
remain in the tumor-bearing lungs.
The lack of persistence of the CD3 mAb-activated CTLs in the
tumor-bearing hosts suggests that these CTLs either failed to
proliferate or simply died in vivo [38,39]. To determine whether
cognate Ag or CD3 mAb induce different proliferation profiles of
the tumor-specific CTLs, we examined the proliferation kinetics of
the tumor-specific CTLs after activation. The tumor cell-
stimulated and CD3 mAb-activated CTLs exhibited almost
identical proliferation kinetics, however, the proliferation rate is
greater in the tumor cell-stimulated CTLs than the CD3 mAb-
stimulated CTLs (Fig. 3C). More importantly, CTLs exhibited
sustained proliferation after repeated Ag stimulation, whereas
repeated stimulation with CD3 mAb resulted in the quick decline
of the proliferation potential of the CTLs (Fig. 3D).
Activation of T cells often results in activation-induced cell
death [37]. To determine whether antigen- and CD3 mAb-
stimulated cells exhibit different apoptosis rates, the CFSE-labeled
CTLs were stimulated with either the AH1 peptide or CD3 mAb
and analyzed for cell division and apoptosis. AH1 peptide is the
peptide that contains the epitope recognized by the CTLs used in
this study [23]. Use of peptide instead of tumor cells reduces the
background for apoptosis analysis. Consistent with what was
observed in
3H incorporation analysis, antigen stimulation induced
faster proliferation rates than CD3 mAb stimulation (Fig. 4A).
However, antigen-stimulated CTLs exhibited less apoptosis than
CD3 mAb-stimulated CTLs (Fig. 4B). Thus, antigen stimulation
leads to greater proliferation and less apoptosis of the tumor-
specific CTLs in vitro.
To determine whether the reduced proliferation potential of the
CD3 mAb-stimulated CTLs is reversible, we stimulated the CTLs
with CD3 mAb for two rounds, and then re-stimulated the CTLs
with tumor cells. CTLs were then analyzed for proliferation in vitro
and tumor rejection efficacy in vivo. It is clear that re-stimulation of
CD3 mAb-stimulated CTLs with antigen can restore the
proliferation potential of the CTLs (Fig. 5A). Consistent with the
restored proliferation potential, CD3 mAb-stimulated cells exhib-
ited potent anti-tumor cytotoxicity in vivo after re-stimulation with
the cognate Ag (Fig. 5B). Thus, we conclude that CD3 mAb
stimulation does not result in senescence and the reduced
proliferation potential of the CD3 mAb-stimulated CTLs is
reversible.
Ifi202 and survivin are differentially induced by cognate
Ag or CD3 mAb
Our data suggest that cognate Ag or CD3 mAb stimulation
results in different proliferation potentials and susceptibility to
apoptosis of the tumor-specific CTLs (Fig. 3&4). To gain a better
understanding of the molecular basis of the different proliferative
potentials of CTLs, we conducted genome-wide gene expression
profiling of the CTLs after stimulation with tumor cells or CD3
mAb, respectively. DNA microarray analysis revealed that,
although their anti-tumor efficacy is dramatically different in vivo,
the gene expression kinetics of the tumor-specific CTLs stimulated
with tumor cells or CD3 mAbs are surprisingly very similar (Fig. 6).
The expression levels of a total of 11964 (out of 36212 genes on the
array chip) were identified to be altered at least 2 fold at either 3 or
24 h after stimulation with tumor cells or CD3 mAb. However,
only 392 genes (3.3%) of the 11964 genes were uniquely regulated
by cognate Ag stimulation, and only 438 genes (3.7%) of the 11964
genes were differentially regulated by CD3 mAb stimulation
(Fig. 6B). Taken together, our data suggest that cognate Ag and
CD3 mAb induce overall similar gene expression profiles in the
tumor-specific CTLs. Nevertheless, a small group of genes are
uniquely associated with cognate Ag or CD3 mAb-induced
activation.
We next focused on genes with known functions in cellular
proliferation and/or apoptosis. Two such genes: ifi202 and survivin,
were identified. Western blotting and RT-PCR analysis confirmed
that the degree of up-regulation of both ifi202 and survivin are
Figure 2. Both antigen and CD3 mAb effectively activate tumor-specific CTLs. A. Activation markers CD69 and CD25 expression kinetics.
CTLs were stimulated with either tumor cells or CD3 mAb for the indicated time points. Cells were stained with CD8-specific mAb plus CD69- or
CD25-specific mAbs, respectively. The CD8-positive cells were gated and measured for CD69 and CD25 mean fluorescent intensity (MFI). B. Analysis
of expression levels of effector molecules of the cytotoxic pathways. CTLs were stimulated with either irradiated tumor cells or CD3 mAb and
harvested at the indicated time points. RT-PCR analysis was carried out using gene-specific PCR primers as indicated. LTb is also used as a
normalization control.
doi:10.1371/journal.pone.0014076.g002
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14076Figure 3. Ag stimulation maintains CTL persistence and proliferative potential. A. CTL persistence in vivo after adoptive transfer. Tumor
cell- or CD3 mAb-stimulated CTLs were labeled with CFSE and injected into tumor-bearing mice. Four days later, lungs were excised from control
mice (no CTL transfer, top left panel), and mice that received CD3 mAb- (top right panel) or tumor cell-stimulated- (bottom panel) CTLs, respectively.
Lungs were digested into single cell suspension and analyzed for CFSE-positive cells by flow cytomotery. B. The percent of CFSE-positive cells as
measured in A were quantified. Column, mean; bar, SD. ** p,0.001. n=5 mice. C. Kinetics of CTL proliferation after activation. CTLs were stimulated
with tumor cells or CD3 mAb and analyzed for
3H-thymidine incorporation over a 6-day period. D. Persistence of proliferation potential of CTLs after
repeated stimulation. CTLs were stimulated with irradiated tumor cells or CD3 mAb every 7 days for a total of 4 rounds.
3H-thymidine incorporation
was measured at day 2 after each re-stimulation.
doi:10.1371/journal.pone.0014076.g003
Figure 4. Antigen and CD3 mAb induce different proliferation and apoptosis profiles of tumor-specific CTLs. A–B. Proliferation
profiles of tumor-specific CTLs. CTLs were labeled with CFSE and stimulated with either antigen or CD3 mAb. CTLs were analyzed for CFSE intensity 3
days after stimulation. Representative proliferation profiles are shown in A. Each division population was then quantified and presented in B. The
percentage of cells in each division population is indicated at the top of the bars. C–D. Analysis of apoptosis of antigen- and CD3 mAb-stimulated
CTLs. The stimulated CTLs as described in A–B were stained with Annexin V and analyzed by flow cytometry. Representative apoptosis profiles are
shown in C. The percentage of apoptotic cells as shown in C were quantified and presented in D. Column, mean; bar, SD.
doi:10.1371/journal.pone.0014076.g004
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CTLs (Fig. 7A). Because expression of ifi202 is predicted to be up-
regulated by IFN-c [40,41,42], we next sought to determine
whether differential ifi202 activation is due to different IFN-cR
levels in the CTLs after tumor cells or CD3 mAb stimulation. Flow
cytometry analysis indicates that IFN-cR is highly expressed in the
CTLs and stimulation resulted in decreased IFN-cR level in the
CTLs. However, tumor cell- and CD3 mAb-stimulated CTLs
expressed similar levels of IFN-cR (Fig. 7B). IFN-c was activated
in the CTLs after stimulation and the IFN-c activation kinetics are
similar under the two activation conditions (Fig. 7C). Thus, the
observed difference in expression levels of ifi202 between tumor
cell- and CD3 mAb-stimulated CTLs are unlikely due to a
difference in IFN-cR levels expressed by the CTLs. IFN-c binding
to the IFN-cR leads to STAT1 phosphorylation. The phosphor-
ylated STAT1 dimerizes and translocates to the nucleus to activate
target genes [43]. To determine whether STAT1 is differentially
activated in CTLs, we examined STAT1 phosphorylation kinetics
in the CTLs after activation. Western blotting analysis revealed
that STAT1 is quickly activated in tumor cell-stimulated CTLs,
but not in CD3 mAb-stimulated CTLs (Fig. 7C). Taken together,
Figure 5. Loss of proliferative potential and anti-tumor
cytotoxicity in CTLs is reversible. A. The loss of proliferation
potential of CD3 mAb-stimulated CTLs is reversible. The tumor-specific
CTLs were re-stimulated with CD3 mAb for 2 times, followed by re-
stimulation with tumor cells. Proliferation was measured by analyzing
3H-thymidine incorporation 2 days after the second tumor cell re-
stimulation. Column, mean; bar, SD. B. The decreased anti-tumor
cytotoxicity of CD3 mAb-stimulated CTLs can be enhanced by antigen
re-stimulation. CTLs were stimulated with tumor cells (Pre-tumor cell) or
CD3 mAb (pre-CD3 mAb) every 7 days for 2 rounds, followed by re-
stimulation with tumor cells twice more rounds before adoptive
transfer. Shown are photomicrographs of individual lungs of mice. The
number of tumor nodules was quantified and shown in the bottom
panel. Each dot represents total tumor nodule counts from a single
mouse.
doi:10.1371/journal.pone.0014076.g005
Figure 6. Gene expression profiles of the tumor-specific CTLs
after tumor cells and CD3 mAb stimulation. A. CTLs were either
stimulated with tumor cells or with CD3 mAb for the indicated time and
analyzed for the genome-scale gene expression profiles using DNA
microarray. Genes whose expression levels are changed by at least 2
fold (either up-regulated or down-regulated) at either time point or
with either stimulation were selected. Cluster 3.0 program was used to
analyze the gene expression patterns in a one-dimensional hierarchical
clustering to generate gene dendrograms based on the pair-wise
calculation of the Pearson coefficient of normalized fluorescence ratios
as measurements of similarity and linkage clustering. The clustered data
were loaded into TreeView program and displayed by the graded color
scheme. B. Differential gene expression profiles between tumor cell-
stimulated and CD3 mAb-activated CTLs. Genes whose expression
levels were either up-regulated or down-regulated more than 2 fold in
tumor cell-activated CTLs but not in CD3 mAb-activated CTLs were
selected as tumor cell-regulated unique genes. Genes whose expression
levels were either up-regulated or down-regulated more than 2 fold in
CD3 mAb-activated CTLs, but not in tumor cell-stimulated CTLs, were
selected as CD3 mAb-regulated unique genes. By these selection
criteria, 93% genes are expressed at similar levels between tumor cell-
or CD3 mAb-activated CTLs. Approximately 3.3% (a total of 392 genes/
transcripts) are antigen-regulated unique genes and 3.7% (a total of 438
genes/transcripts) are CD3 mAb-regulated unique genes.
doi:10.1371/journal.pone.0014076.g006
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activation, whereas CD3 mAb is unable to activate STAT1 and
thus results in defective IFN-c signaling in the CTLs, which might
be responsible, at least in part, for the lack of ifi202 and survivin up-
regulation in the activated CTLs.
STAT1 directly regulates survivin and ifi202 expression
Our above observations indicate that survivin expression in the
tumor-specific CTLs is not only differentially induced by tumor
cells and CD3 mAb stimulation (Fig. 7A) but also correlated with
STAT1 activation (Fig. 7C), suggesting that survivin might also be a
target gene of the IFN-c signaling pathway. To test this hypothesis,
we used the T cell line 5KC [24] to examine the role of the IFN-c
signaling pathway on survivin expression. Flow cytometry analysis
indicates that IFN-cR is highly expressed on the cell surface of
5KC cells, and treatment of 5KC cells with recombinant IFN-c
induced STAT1 phosphorylation (pSTAT1) and increased
STAT1 expression (Fig. 8A). Furthermore, IFN-c treatment also
increased ifi202 and survivin expression (Fig. 8A). Thus, 5KC T
cells resemble the tumor-specific CTLs in terms of IFN-c signaling
and survivin and ifi202 expression, and thus is a model system to
study regulation of ifi202 and survivin expression. pSTAT1 is a
transcription factor that binds to a consensus sequence termed
Gamma Activation Sequence or GAS (TTC(n2-4)GAA) [44]. To
determine whether pSTAT1 binds directly to the survivin gene
promoter, we identified the survivin gene sequence from the mouse
genome sequence database. Analysis of the promoter region of the
survivin gene using the MacVector program identified a GAS
element located between -1287 to -1279 relative to the survivin gene
transcription initiation site (Fig. 8B). Analysis of pSTAT1
association with the chromatin region containing this GAS
element using ChIP revealed that pSTAT1 is associated with this
region of the chromatin in 5KC cells (Fig. 8B). To determine
whether pSTAT1 binds directly to this GAS DNA element of the
Figure 7. Ifi202 and survivin are differentially expressed between the tumor cell-and CD3 mAb-activated CTLs. A. RT-PCR and Western
blotting analysis of ifi202 and survivin expression level during CTLs activation. CTLs were stimulated with either tumor cells or CD3 mAb for the
indicated time and analyzed by RT-PCR (left panel) and Western blotting (right panel). B. Cell surface IFN-cR staining of CTLs. CTLs were either un-
stimulated (0 h) or stimulated with tumor cells or CD3 mAb for 24 h, respectively. The CTLs were then double stained with anti-CD8- and anti-IFN-cR-
specific mAbs. The figure is representative of three IFN-cR staining profiles of CD8
+ cells. Bottom panel: the mean fluorescent intensity (MFI) of IFN-cR
was quantified and shown as mean6SD. Column: mean; bar, SD. P,0.001. C. STAT1 is preferentially activated in tumor cell-activated CTLs. CTLs were
activated as in A and analyzed for IFN-c transcript level by RT-PCR (left panel) and for phosphorylated STAT1 level by Western blotting analysis (right
panel). The Western blot shown is representative of two separate experiments.
doi:10.1371/journal.pone.0014076.g007
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GAS element and made a double-stranded probe. Incubation of
nuclear extract derived from IFN-c-treated 5KC cells and analysis
of pSTAT1 and the GAS probe interaction using EMSA showed
that pSTAT1 binds specifically and directly to this GAS element
(Fig. 8B). Taken together, our data suggest that survivin is a direct
target gene of the IFN-c signaling pathway during T cell
activation.
Although expression of the ifi202 is predicted to be up-regulated
by IFN-c [42], it is not fully understood how IFN-c regulates ifi202
expression. We analyzed the 59-regulatory region of the ifi202
gene and identified 7 potential GAS elements in the upstream
5000 nucleotide sequence relative to the potential ifi202 gene
transcription initiation site (Fig. 8C). ChIP analysis indicated that
pSTAT1 is associated with the promoter region near the
transcription start site (Fig. 8C). Thus, IFN-c-activated STAT1
is also directly associated with the ifi202 59-regulatory region to
regulate ifi202 expression.
Silencing ifi202 expression decreased T cell proliferation
It is known that increased expression of ifi202 inhibits apoptosis
[41,45,46]. We observed here a positive correlation between p202
protein level and CTL persistence (Fig. 7). To determine whether
the p202 protein mediates T cell proliferation and survival, we
silenced the ifi202 expression with ifi202-specific shRNA (Fig. 9A).
It is clear that silencing ifi202 expression significantly inhibited
5KC T cell proliferation (p,0.01). Thus, ifi202 plays a direct role
in T cell proliferation and/or survival.
Figure 8. Ifi202 and survivin expression is directly regulated by the IFN-c signaling pathway. A. IFN-c induces ifi202 and survivin
expression in T cells. T cell line 5KC was stained for IFN-cR protein level (top panel), and treated with IFN-c for the time indicated and analyzed for
STAT1 activation (middle panel) and induction of ifi202 and survivin (bottom panel). B. IFN-c-activated STAT1 (pSTAT1) binds to the survivin promoter
region. Top left panel: survivin promoter structure. Number above the bar indicates nucleotide positions relative to survivin transcription initiation
site. The GAS element location and the ChIP PCR region are indicated under the bar. Bottom left panel: ChIP analysis of pSTAT1 association with the
survivin promoter. 5KC cells were treated with IFN-c for approximately 24 h and analyzed by ChIP with pSTAT1-specific mAb and survivin promoter-
specific PCR. Right panel: EMSA of pSTAT1 and the GAS element of the survivin promoter. Nuclear extracts were prepared from untreated (lanes 2 and
8) and IFN-c-treated (lanes 3–7 and 9) 5KC cells. Nuclear extracts were incubated in the presence of isotype control IgG mAb (lane 4), anti-pSTAT1
mAb (lane 5), excess cold probe (lane 6) and mutant cold probe (lane 7). Lanes 1–7: probe of survivin promoter GAS element. Lanes 8 and 9: probe of
IRF8 GAS element. C. IFN-c-activated STAT1 binds to the ifi202 59-regulatory region. Top panel: ifi202 regulatory region structure. Number above the
bar indicates nucleotide positions relative to ifi202 transcription initiation site. The GAS elements and the ChIP PCR-amplified regions are indicated
under the bar. Bottom panel: ChIP analysis of pSTAT1 association with the survivin promoter. 5KC cells were treated with IFN-c for approximately 24 h
and analyzed by ChIP with pSTAT1-specific mAb and ifi202 gene-specific PCR.
doi:10.1371/journal.pone.0014076.g008
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It is a well-established concept that T cells require Ag and co-
stimulation signals for activation and proliferation. It has also been
shown that a third molecular signal such as IL-2 is required for
optimal T cell activation and proliferation [20]. In this study, we
observed that stimulation of tumor-specific CTLs through the
TCR/CD3 complex and co-stimulation molecule CD28 resulted
in suboptimal proliferation and subsequent loss of proliferative
potential. This activation-induced non-responsiveness is apparent-
ly not due to lack of IL-2 production by the activated CTLs since
recombinant IL-2 is included in the culture medium. Furthermore,
this non-responsive state is reversible by Ag stimulation, suggesting
that the non-responsive CTLs are not senescent. It is known that
re-stimulation of T lymphocytes through the TCR/CD3 complex
also induces activation-induced cell death (AICD) and AICD is
mediated by Fas/FasL-mediated apoptosis [47]. In this study, we
observed that FasL is quickly up-regulated in both Ag- and CD3
mAb-stimulated CTLs (Fig. 2B) and a portion of the proliferating
CTLs are apoptotic (Fig. 4C). It seems that CD3 mAb stimulation
results in less proliferation and more apoptosis than Ag
stimulation, which might at least partially explain the decreased
tumor rejection efficacy of the CD3 mAb-stimulated CTLs.
To elucidate the molecular mechanisms underlying CD3 mAb
stimulation-induced non-responsiveness of the tumor-specific
CTLs, we carried out genome-wide gene expression analysis and
observed that ifi202 and survivin, two genes with known function in
apoptosis and proliferation, are differentially expressed between
Ag- and CD3 mAb-stimulated CTLs. Ifi202 is an IFN-inducible
protein and plays a role in the regulation of apoptosis [41,42,45].
Inhibition of the endogenous ifi202 increased susceptibility to
apoptosis induction [48], and overexpression of ifi202 in cells
induced to undergo p53-dependent apoptosis significantly delayed
this process [49], suggesting that ifi202 functions as an apoptosis
inhibitor. In this study, we observed that ifi202 is quickly up-regulated
in tumor-specific CTLs after antigenic stimulation. Therefore, the
lack of ifi202 up-regulation in CD3 mAb-stimulated CTLs might
contribute to the lack of CTL persistence in the tumor microenvi-
ronment (Fig. 3A) and decreased tumor rejection efficacy in vivo
(Fig. 1).
Survivin expression is strictly regulated in T cells and plays an
essential role in T cell maturation, survival and proliferation
[50,51,52,53,54,55,56]. Survivin-deficient cells exhibited cell cycle
arrest and increased cell death [52], and blocking survivin
suppressed T cell proliferation and led to apoptosis [53]. These
observations thus suggest that survivin plays an important role in T
cell maturation, activation and apoptosis. Consistent with these
observations, Ag-reactive T cells expressing survivin exhibited long-
term survival and displayed enhanced anti-tumor activity [55]. In
this study, we observed that survivin is rapidly up-regulated in
tumor-specific CTLs after antigenic stimulation. Up-regulation of
survivin is associated with sustained proliferation potential of the
CTLs and is correlated with tumor-specific CTL persistence in the
tumor microenvironment and tumor rejection efficacy in vivo. CD3
mAb stimulation apparently activated the tumor-specific CTLs
(Fig. 2A) and the cytotoxic effecter mechanisms (Fig. 2B).
However, CD3 mAb-activated tumor-specific CTLs failed to up-
regulate survivin, which might explain, at least partially, why CD3
mAb-activated tumor-specific CTLs failed to persist in cancer
patients after adoptive transfer [14].
The above studies strongly suggest that the expression of survivin
is tightly regulated during T cell activation. However, the
molecular mechanisms underlying the regulation of survivin
expression are not entirely clear. Our study indicates that survivin
is directly regulated by IFN-c. Engagement of the IFN-cR leads to
receptor a-chain dimerization, association of b-chains, transphos-
phorylation of the receptor-associated JAK kinases, and ultimately
to phosphorylation and dimerization of STAT1, which is then
translocated to the nucleus as an active transcription factor [57].
Therefore, STAT1 is a key mediator of the IFN-c-initiated
Figure 9. Silencing ifi202 expression decreased T cell proliferation. A. Silencing of ifi202 expression by ifi202-specific shRNA. 5KC cells were
transduced with scramble shRNA-expressing lentiviral particles (5KC.scramble) and ifi202-specific shRNA (5KC.ifi202.shRNA), respectively. The
transduced cells were selected with puromycin for stable lines and analyzed for ifi202 expression by RT-PCR. B. Silencing ifi202 expression decreased T
cell proliferation. 5KC.scramble and 5KC.ifi202.shRNA cells were seeded in 96-well plates at the indicated density in the presence of IFN-c (100 U/ml)
for approximately 48 h and analyzed by MTT assay. ** p,0.01. C. Cells were seeded in a 96-well plate as described in B at a density of 3610
3 cells/well
and measured for
3H incorporation. ** p,0.01.
doi:10.1371/journal.pone.0014076.g009
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binds directly to a GAS element in the survivin promoter region to
activate survivin expression (Fig. 8). IFN-c is secreted by activated T
cells (Fig. 7C). Thus, survivin expression during T cell activation is
regulated by the activated T cell-secreted IFN-c in an autocrine
manner. Our data indicate that IFN-c can quickly induce STAT1
phosphorylation in antigen-activated CTLs but not in CD3 mAb-
activated CTLs (Fig. 7C). Therefore, the lack of survivin up-
regulation in CD3 mAb-activated CTLs is likely due to the lack of
STAT1 activation. The molecular mechanism underlying the
failure of CD3 mAb to induce STAT1 activation remains to be
determined. Nevertheless, our results indicate a novel role of IFN-
c during T cell activation: regulating survivin expression to
maintain CTL proliferation potential and suppress apoptosis.
It has been shown that CD8
+ effector cells expressing survivin
and bcl-xL exhibit greater proliferation rates and long-term
survival advantages. The survivin and bcl-xL-expressing T cells also
exhibit greater tumor rejection efficacy [55]. We also observed
that survivin up-regulation is associated with increased proliferation
and enhanced tumor rejection efficacy. Furthermore, our data
suggest that survivin expression in T cells is regulated by IFN-c.
Therefore, survivin-mediated T cell proliferation potential might
be a general phenomenon. The role of bcl-xL in regulating tumor-
specific CTL proliferation and tumor rejection efficacy is not
investigated in this study.
It has been well-demonstrated that IFN-c plays an essential role
in suppressing tumor development [1,2,58] and that IFN-c
signaling on tumor cells is important for IFN-c-mediated anti-
tumor activity. It is also known that IFN-c/STAT1 signaling on
host immune cells is essential for the development of anti-tumor
lytic effecter cells [59]. Type I IFNs have also been shown to
provide a third signal directly to CTLs via a STAT4-dependent
pathway for CTL survival, function and IFN-c production [60].
However, how IFN-c regulates effecter cells is not well-defined. It
is known that co-stimulation is required for T cell proliferation,
survival and differentiation. Co-stimulation induces expression of
bcl-xL and survivin and thus promotes cell survival [55,61]. In this
study, we observed that stimulation of tumor-specific CTLs with
CD3 mAb in the presence of a costimulation signal from CD28
failed to maintain CTL proliferation in vitro and persistence in vivo.
In contrast, stimulation with tumor cells maintained CTL
proliferation potential and persistence. Furthermore, CTL-pro-
duced IFN-c directly up-regulates survivin and ifi202 expression in
an autocrine manner. Therefore, it seems that IFN-c might
function as a ‘‘third signal’’ to mediate CTL proliferation and
survival [20,60]. Our data suggest that IFN-c might execute its
anti-tumor function, at least partially, through regulating survivin
and ifi202 expression to maintain T cell persistence in the tumor
microenvironment. We demonstrated that IFN-c activates STAT1
to directly regulate survivin and ifi202 expression during Ag-
mediated T cell activation. Up-regulation of survivin might be
essential for CTL proliferation potential and persistence in the
tumor microenvironment, whereas up-regulation of ifi202 might
prevent or delay apoptosis of activated T cells. Thus, our
observations suggest a novel function of the IFN-c signaling
pathway in maintaining CTL persistence and might aid in
designing survivin and ifi202-based strategies to maintain CTL
persistence to enhance CTL function in cancer immunotherapy.
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